These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. A Novel Tool to Identify Bactericidal Compounds against Vulnerable Targets in Drug-Tolerant M. tuberculosis found in Caseum. Sarathy JP; Xie M; Jones RM; Chang A; Osiecki P; Weiner D; Tsao WS; Dougher M; Blanc L; Fotouhi N; Via LE; Barry CE; De Vlaminck I; Sherman DR; Dartois VA mBio; 2023 Apr; 14(2):e0059823. PubMed ID: 37017524 [TBL] [Abstract][Full Text] [Related]
9. Oxygen Modulates the Effectiveness of Granuloma Mediated Host Response to Mycobacterium tuberculosis: A Multiscale Computational Biology Approach. Sershen CL; Plimpton SJ; May EE Front Cell Infect Microbiol; 2016; 6():6. PubMed ID: 26913242 [TBL] [Abstract][Full Text] [Related]
10. Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating Srivastava S; Cirrincione KN; Deshpande D; Gumbo T Front Pharmacol; 2020; 11():616294. PubMed ID: 33542690 [No Abstract] [Full Text] [Related]
11. A novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis generates a lipid-loaded, drug-tolerant, dormant pathogen. Deb C; Lee CM; Dubey VS; Daniel J; Abomoelak B; Sirakova TD; Pawar S; Rogers L; Kolattukudy PE PLoS One; 2009 Jun; 4(6):e6077. PubMed ID: 19562030 [TBL] [Abstract][Full Text] [Related]
12. Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis. Hu Y; Coates AR; Mitchison DA Int J Tuberc Lung Dis; 2006 Mar; 10(3):317-22. PubMed ID: 16562713 [TBL] [Abstract][Full Text] [Related]
14. Metronidazole lacks activity against Mycobacterium tuberculosis in an in vivo hypoxic granuloma model of latency. Klinkenberg LG; Sutherland LA; Bishai WR; Karakousis PC J Infect Dis; 2008 Jul; 198(2):275-83. PubMed ID: 18491971 [TBL] [Abstract][Full Text] [Related]
15. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
16. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy. de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361 [TBL] [Abstract][Full Text] [Related]
18. Identification of Novel Anti-mycobacterial Compounds by Screening a Pharmaceutical Small-Molecule Library against Nonreplicating Mycobacterium tuberculosis. Warrier T; Martinez-Hoyos M; Marin-Amieva M; Colmenarejo G; Porras-De Francisco E; Alvarez-Pedraglio AI; Fraile-Gabaldon MT; Torres-Gomez PA; Lopez-Quezada L; Gold B; Roberts J; Ling Y; Somersan-Karakaya S; Little D; Cammack N; Nathan C; Mendoza-Losana A ACS Infect Dis; 2015 Dec; 1(12):580-5. PubMed ID: 27623055 [TBL] [Abstract][Full Text] [Related]
19. Drug targets in dormant Mycobacterium tuberculosis: can the conquest against tuberculosis become a reality? Gupta VK; Kumar MM; Singh D; Bisht D; Sharma S Infect Dis (Lond); 2018 Feb; 50(2):81-94. PubMed ID: 28933243 [TBL] [Abstract][Full Text] [Related]
20. Potential effect of ezetimibe against Mycobacterium tuberculosis infection in type II diabetes. Tsai IF; Kuo CP; Lin AB; Chien MN; Ho HT; Wei TY; Wu CL; Lu YT Respirology; 2017 Apr; 22(3):559-566. PubMed ID: 27879023 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]